Scholars Central

Conference abstractPublished 12 Jul 2018

Therapeutic potential of activated mesenchymal stem cells in chronic myocardial infarction â?? as novel strategic cell therapy

Authors: Akifumi Matsuyama, Hanayuki Okura

Fujita Health University, Japan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Cell therapy is promising for cardiac diseases and lots of trials have been challenged. Many reported showed their efficacy in the investigational trials, but few showed dropout in the large pivotal ones. Here, we supposed that MSCs-activation could overcome them. In this study, we propose the novel strategy to identify the bio-active protein which could activate MSCs and show the activated MSCs could improve the cardiac dysfunction. Methods & Results: hADMPCs, as the representatives of MSCs, were challenged to 160 kinds of bio-actives, and the cells were applied for DNA microarray analysis. Principal component analysis showed seven bio-actives could prime hADMPCs. IL-1β was selected as the activating reagent for them, because IL-1β-activated ones could show augmented probes. To confirm the activated hADMPCs could improve cardiac dysfunction, the cells were applied for the chronic myocardial infarction swine models. The animals were injected with hADMPCs, IL-1β-activated ones (3x105 cells/kg body) or placebo via the coronary artery. Cardiac function was assessed by MRI at 0 and 12-week post-transplantation. IL-1β-activated hADMPC-administration showed significant improvement than those of hADMPCs and controls (Î?EF% of controls were -1.0%, hADMPCs, 4.5% and IL-1β-activated hADMPCs 9.0%, respectively). Histological analysis showed significant reduction of fibrotic area of the cardiac tissues, the number of cardiomyocytes were increased, and the vascular network has been reconstructed in IL-1β-activated ones-treated animals. Conclusion: We showed the novel strategy to identify IL-1β as MSCs-activating reagents and show the IL-1β-activated MSCs could be applicable for therapeutics to chronic myocardial infarction.

Subjects

Engineering

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Tissue Science and Engineering.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Tissue Science and Engineering
  • SubjectEngineering
  • BylineArticles whose byline prints “Akifumi Matsuyama”
  • BylineArticles whose byline prints “Hanayuki Okura”